Difference between revisions of "Lung carcinoma with ALK rearrangement"

Lung carcinoma with ALK rearrangement (view source)

452 bytes added , 13:17, 19 October 2017

no edit summary

48,453

edits

@@ Line 8: / Line 8: @@
 ***Resistance to ALK inhibitors may occur due mutations in kinase domain.
 ***Ceritinib is indicated for tumor with acquired resistance to crizotinib.<ref>{{Cite journal  | last1 = Shaw | first1 = AT. | last2 = Kim | first2 = DW. | last3 = Mehra | first3 = R. | last4 = Tan | first4 = DS. | last5 = Felip | first5 = E. | last6 = Chow | first6 = LQ. | last7 = Camidge | first7 = DR. | last8 = Vansteenkiste | first8 = J. | last9 = Sharma | first9 = S. | title = Ceritinib in ALK-rearranged non-small-cell lung cancer. | journal = N Engl J Med | volume = 370 | issue = 13 | pages = 1189-97 | month = Mar | year = 2014 | doi = 10.1056/NEJMoa1311107 | PMID = 24670165 }}</ref>
+*Testing in FFPE requires ~100 cells.<ref name=pmid25806315>{{Cite journal  | last1 = Popper | first1 = HH. | last2 = Tímár | first2 = J. | last3 = Ryska | first3 = A. | last4 = Olszewski | first4 = W. | title = Minimal requirements for the molecular testing of lung cancer. | journal = Transl Lung Cancer Res | volume = 3 | issue = 5 | pages = 301-4 | month = Oct | year = 2014 | doi = 10.3978/j.issn.2218-6751.2014.10.02 | PMID = 25806315 }}</ref>
 ==Microscopic==